the cme on treatment of androgenetic alopecia in ludhiana
TRANSCRIPT
www.akclinics.com
Evidence Based Treatment Update in Androgenetic Alopecia
for Men
www.akclinics.comHair Follicle Growth Cycle
Anagen/Active Growth Phase : 2-6 years
Catagen/Transition Phase : 1-2 weeks
Telogen/Resting Phase : 1-2 months
www.akclinics.comHair Types
Terminal hairs are thick, long, and dark, as compared with vellus hairs which are short, fine and light-colored
Vellus hairs develop into terminal hairs during and after puberty
www.akclinics.comAndrogenetic Alopecia (AGA) Loss of hair with increasing age in genetically predisposed
individuals Decreased anagen and increased telogen Affects both males & females Characterized by
Miniaturization of the hair follicle Reduction in thickness of hair shaft Decrease in hair density Reduced hair growth rate
www.akclinics.comAndrogenetic Alopecia
Androgenetic alopecia is characterized by the gradual conversion of terminal hairs into indeterminate and finally into vellus hairs
www.akclinics.comAndrogenetic Alopecia: Male Men experience receding of frontal hairline and/or vertex
baldingHamilton-Norwood classification
www.akclinics.comAndrogenetic Alopecia: Female Women experience diffuse thinning over the entire top of the
head i.e. vertex
Ludwig classification
www.akclinics.comAndrogenetic Alopecia: Pathophysiology
Role of Dihydrotestosterone (DHT)
Testosterone Dihydrotestosterone5-α Reductase
Androgenetic Alopecia
Shortens Anagen
www.akclinics.comAndrogenetic Alopecia: Pathophysiology
Role of Dihydrotestosterone (DHT)
www.akclinics.comTreatment of Androgenetic Alopecia: Evidence Based
www.akclinics.comTreatment Options
Medical Miscellaneous Surgical Light Therapy
www.akclinics.com
1. Am J Clin Dermatol. 2014; 15: 217-230. 2. J Dtsch Dermatol Ges. 2011; 9 Suppl 6: S1-57.
www.akclinics.comLevel of Evidence
J Dtsch Dermatol Ges. 2011; 9 Suppl 6: S1-57.
www.akclinics.comMinoxidil
Am J Clin Dermatol. 2014; 15: 217-230.
www.akclinics.comMinoxidil
J Dtsch Dermatol Ges. 2011; 9 Suppl 6: S1-57.
www.akclinics.com5-Alpha Reductase Inhibitors
Am J Clin Dermatol. 2014; 15: 217-230.
www.akclinics.com5-Alpha Reductase Inhibitors
J Dtsch Dermatol Ges. 2011; 9 Suppl 6: S1-57.
www.akclinics.com5-Alpha Reductase Inhibitors
J Dtsch Dermatol Ges. 2011; 9 Suppl 6: S1-57.
www.akclinics.comHormonal treatment
Am J Clin Dermatol. 2014; 15: 217-230.
www.akclinics.comHormonal treatment
J Dtsch Dermatol Ges. 2011; 9 Suppl 6: S1-57.
www.akclinics.comHormonal treatment
J Dtsch Dermatol Ges. 2011; 9 Suppl 6: S1-57.
www.akclinics.comCombination treatment
Am J Clin Dermatol. 2014; 15: 217-230.
www.akclinics.comMiscellaneous
Am J Clin Dermatol. 2014; 15: 217-230.
www.akclinics.comMiscellaneous
Am J Clin Dermatol. 2014; 15: 217-230.
www.akclinics.comSurgery
Important role in AGA patients who do not have success with medical therapies
Include hair transplantation and scalp reduction or a combination of both
Considered to have insufficient evidence in both sexes
Limitation of not having efficacy in preventing the progression of AGA
Long-term combination therapy of hair transplantation and oral finasteride 1 mg daily in male patients has been suggested
Am J Clin Dermatol. 2014; 15: 217-230.
www.akclinics.comSurgery
J Dtsch Dermatol Ges. 2011; 9 Suppl 6: S1-57.
www.akclinics.comLow-level light therapy (LLLT) Various products using LLLT, including comb, hood, and
helmet are available LLLT, particularly 650–900 nm wavelength at 5 mW, may be
an effective alternative treatment for AGA patients either as a stand-alone or adjunctive therapy
Am J Clin Dermatol. 2014; 15: 217-230.
www.akclinics.comConclusion Medical treatment in terms of efficacy and safety with the best level
of evidence include topical minoxidil and oral finasteride
Topical minoxidil appears to be the most effective and safe treatment in females
There is limited evidence to conclude the efficacy of hormonal treatment
Various miscellaneous agents are claimed to have some role
Follicular unit hair transplantation is a good option when medical treatment is not effective
Light therapy may be an alternative treatment option
Am J Clin Dermatol. 2014; 15: 217-230.
www.akclinics.comwww.akclinics.com
s
…THANK YOU
We’re committed to transform looks…
----------------------------+91 97 7994 42 07+91 97 7916 21 90
There is a wide scope for improvement in everything